Richard Dean Dr McCormick
Richard Dean Dr McCormick (R-GA) bought $1K-$15K of $ABT (Abbott Laboratories Common Stock) on Mar 19, 2026, part of 20 transactions in this filing (12 buys, 8 sells).
HillSignal flagged 5 timing concerns on this filing — trades that line up closely with related legislative or contract activity.
Companies in this filing · 11
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Showing the 6 largest positions. See every transaction in the table below.
Suspicious Timing Detected
5 flagsRichard Dean Dr McCormick bought $1,001 - $15,000 in $UNH on 2026-03-19, 7 days before HR8129, a bill to establish a full risk ACO program, was introduced. This bill could expand the market for large health organizations.
Richard Dean Dr McCormick bought $1,001 - $15,000 in $UNH on 2026-03-19, 11 days before HR8163, a bill to ensure stability for provider payments under Medicare, was introduced. This bill could benefit managed care organizations.
Richard Dean Dr McCormick sold $1,001 - $15,000 in $JNJ on 2026-03-19, 8 days before HR8143, a bill to require Medicare Part D plans to include certain generic drugs, was introduced. This bill could reduce brand-name drug sales.
Richard Dean Dr McCormick bought $1,001 - $15,000 in $MSFT on 2026-03-19, 26 days before a $25.6M GSA contract for Geotab USA Inc. was announced. This contract indicates federal investment in fleet management technology.
Richard Dean Dr McCormick bought $1,001 - $15,000 in $MSFT on 2026-03-19, 30 days before a $94.7M Department of Agriculture contract for Palantir Technologies Inc. was announced. This contract is for modernizing IT systems.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | US Treasury Bill | US Treasury Bill(US Treasury Bill) | $100K-$250K | — | — | — | Dec 12, 2025 |
| BUY | $ABT | Abbott Laboratories Common Stock | $1K-$15K | $107.19 | $91.07 | -15.0% | Mar 19, 2026 |
| BUY | $ADP | Automatic Data Processing, Inc. - Common Stock | $1K-$15K | $210.66 | $231.95 | +10.1% | Mar 19, 2026 |
| BUY | $BLK | BlackRock, Inc. Common Stock | $1K-$15K | $969.60 | $995.60 | +2.7% | Mar 19, 2026 |
| BUY | $HD | Home Depot, Inc. | $1K-$15K | $328.21 | $310.78 | -5.3% | Mar 19, 2026 |
| BUY | $HD | Home Depot, Inc. | $1K-$15K | $328.21 | $310.78 | -5.3% | Mar 19, 2026 |
| BUY | $MSFT | Microsoft Corporation - Common Stock | $1K-$15K | $389.02 | $416.67 | +7.1% | Mar 19, 2026 |
| BUY | $MSFT | Microsoft Corporation - Common Stock | $1K-$15K | $389.02 | $416.67 | +7.1% | Mar 19, 2026 |
| BUY | $UNH | UnitedHealth Group Incorporated Common Stock | $1K-$15K | $280.44 | $399.47 | +42.4% | Mar 19, 2026 |
| BUY | $UNH | UnitedHealth Group Incorporated Common Stock | $1K-$15K | $280.44 | $399.47 | +42.4% | Mar 19, 2026 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Parents Decide Act
HR8250 (Parents Decide Act) introduces mandatory age verification for operating systems, creating new compliance costs and user acquisition friction for AAPL, GOOGL, and MSFT. The bill is early-stage (referred to committee) with no funding appropriation and an uncertain legislative path. Market data shows AAPL and GOOGL near 52-week highs, while MSFT has pulled back 5% in the last week.
DLA TROOP SUPPORT: $65.0M Department of Health and Human Services Contract
This $65.0 million contract for pharmaceuticals and related supplies, awarded to DLA Troop Support by the NIH, is likely to benefit major pharmaceutical companies as prime or sub-contractors, driven by ongoing federal healthcare needs. The award aligns with legislative support for healthcare services, suggesting a stable demand environment.
To amend title XVIII of the Social Security Act to establish a full risk ACO program.
HR8129, a bill to create a permanent full risk ACO program in traditional Medicare, is at early legislative stage with low momentum (1 cosponsor, 2 committees). Despite this, the four largest Medicare Advantage insurers ($UNH, $HUM, $CNC, $CVS) have already rallied sharply over 30 days — $CNC +62.34%, $HUM +38.49%, $UNH +35.85%, $CVS +16.05% — indicating investors are pricing in the structural shift to value-based care regardless of this specific bill's passage timeline.
To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program.
HR8163 (Provider Reimbursement Stability Act) is an early-stage procedural bill that reduces physician fee cut frequency under Medicare budget neutrality rules, directly benefiting Medicare Advantage insurers. $UNH, $CVS, and $HUM have rallied 3-12% in the past week on bipartisan momentum signals, though zero authorized funding means zero direct revenue impact—only regulatory relief.
To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
HR8143 mandates Medicare Part D formularies give preferred placement to generic drugs and biosimilars with lower wholesale acquisition costs than brand-name reference products, effective January 1, 2027. This directly benefits pure-play generics manufacturers $VTRS and $TEVA by guaranteeing formulary access and restricting PBM utilization management. The bill is early stage (referred to committee) but has bipartisan sponsorship and clear structural impact on the Part D market.
Ensuring Medicaid Continuity for Children in Foster Care Act of 2026
HR8095 is a narrow technical fix allowing federal Medicaid payments for children in foster care placed in qualified residential treatment programs. The bill authorizes zero funding and is at an early legislative stage (referred to committee). Recent rallies in Medicaid MCO stocks like CNC (+62.37% 30-day) and MOH (+46.63% 30-day) are driven by broader sector dynamics, not this niche bill.
Ultra-Millionaire Tax Act of 2026
HR8085 (Ultra-Millionaire Tax Act of 2026) proposes a 2-3% annual wealth tax on net assets above $50 million. The bill is at early stage—referred to Ways and Means with 45 Democratic cosponsors. Asset managers BLK, MS, and GS face structural headwinds from potential capital outflow, though passage remains highly uncertain. Real market data shows mixed performance: BLK ($1061.84, +1.61% 7-day), MS ($188.87, +0.43% 7-day), and GS (implied from data, declined -0.89% 7-day as of 2026-04-28) signaling market is pricing in legislative risk.
Grid Expansion and Reliability Act
HR8248 (Grid Expansion and Reliability Act) would allow self-certification to FERC for transmission lines in NIETCs, bypassing state siting barriers. The bill is early-stage (referred to committee) and authorizes no funds, but the regulatory streamlining is net bullish for transmission equipment manufacturers ($ETN) and utilities with large FERC-jurisdictional transmission capex ($AEP, $WEC). Real market data shows these names up 1-7% over the past week on broader utility tailwinds.
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
HR8032 (FAIC Act) is an early-stage bill requiring separate Medicare Part B payment for qualifying cancer drugs, eliminating a hospital incentive to avoid expensive branded oncology therapies. The bill protects $50B+ in oncology drug revenue for major pharma companies but faces a long legislative path through two committees. Current stock prices for affected tickers are near the bottom of their 52-week ranges, suggesting market pessimism is already priced in, creating asymmetric upside if the bill advances.
DPA Private-Sector Outreach Act of 2026
HR8038 is an early-stage procedural bill to streamline private-sector access to DPA authorities; its market relevance is amplified by the Apr 20 DPA Section 303 determinations that already accelerated grid, gas, and energy infrastructure investment. Real market data confirms capital moving into energy and infrastructure stocks: $NEE +1.13% and $KMI +2.93% in the 7 days ending Apr 30, while $CAT surged +7.23% over the same week. The bill authorizes zero funding itself but creates a durable bureaucratic mechanism for companies to access DPA priority contracting, making it a structural positive for energy equipment, infrastructure, and utility developers.
Other Filings by Richard Dean Dr McCormick
Free — no credit card
Get the next McCormick trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.